Cerebral Spinal Articles & Analysis
6 news found
Results from initial CY6463 clinical studies have demonstrated favorable safety and tolerability and pharmacologically relevant drug exposure in the cerebral spinal fluid. Furthermore, promising impacts on EEG measures, neuroinflammation, and other measures support the current clinical development of CY6463. ...
FONAR has new works-in-progress technology for visualizing and quantifying the cerebral hydraulics of the central nervous system, the flow of cerebrospinal fluid (CSF), which circulates throughout the brain and vertebral column at the rate of 32 quarts per day. ...
We think that further understandings of CSF flow may lead to new understanding of the role of CSF on the neurodegenerative diseases such as Multiple Sclerosis, Alzheimer's, ALS, Parkinson's, Autism, Cerebral Palsy, Huntington's and Epilepsy.” About FONAR FONAR, the Inventor of MR Scanning™, located in Melville, NY, was incorporated in 1978, and is the first, oldest ...
The device is located under the scalp, much like a cerebral spinal fluid (CSF) shunt. In March, the company received FDA breakthrough device designation for its ReFlow System Mini intended for the treatment of CSF disorders requiring shunting, such as hydrocephalus. ...
Anuncia Inc., an emerging leader in Cerebral Spinal Fluid (CSF) management, received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for its ReFlow™ System Mini intended for the treatment of CSF disorders requiring shunting such as hydrocephalus, a debilitating and life-threatening condition affecting more than 1 million U.S. ...
Using Veravas’ proprietary sample prep technology in conjunction with Tymora’s extracellular vesicle enrichment technology, the partnership will focus on developing the world’s first diagnostic test for Alzheimer’s Disease (AD) from human plasma samples as an alternative to current cerebral spinal fluid (CSF) neuromarker testing. Early ...